GleamWall
中文EN

RGEN REPLIGEN CORP

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 730272 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.8%
TTM net income YoY-779.2%
TTM EPS YoY-1,150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.8%
Operating margin2.3%
Net margin-1.5%
FCF margin13.2%
EBITDA margin11.9%

Returns

ROE-0.6%
ROA-0.4%
ROIC (approx.)0.5%
Asset turnover0.28x

Leverage & solvency

Liabilities / assets28.5%
Debt / equity0.27x
Current ratio9.88x
Interest coverage0.81x

Cash quality & payout

Operating cash flow / net income-11.00x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$209.31M$204.13M$194.25M$197.91M$188.81M$182.37M$169.17M$167.55M
Cost of revenue$98.33M$94.09M$85.97M$94.08M$88.29M$89.37M$77.80M$128.71M
Gross profit$110.99M$110.04M$108.28M$103.83M$100.52M$93.00M$91.37M$38.84M
R&D expense$14.44M$14.42M$14.46M$13.12M$14.18M$13.97M$12.11M$11.68M
SG&A expense$83.59M$76.62M$76.54M$74.36M$73.66M$70.91M$70.71M$60.47M
Operating income-$29.55M$13.98M$15.94M$17.87M$16.82M$13.90M$6.58M-$36.50M
Interest expense$5.71M$5.66M$5.58M$5.50M$5.41M$5.35M$5.25M$5.46M
Pretax income-$26.81M$14.15M$1.77M$19.11M$17.11M$18.21M$7.94M-$38.61M
Income tax$11.62M$9.14M-$6.56M$5.83M$2.20M$3.35M$2.11M-$4.74M
Net income-$38.43M$5.01M$8.33M$13.29M$14.91M$14.87M$5.83M-$33.87M
EBITDA-$10.42M$33.04M$35.70M$37.82M$36.83M$33.98M$25.28M-$18.13M
EPS (basic)-0.680.090.15—0.270.260.10—
EPS (diluted)-0.680.090.15—0.260.260.10—
Weighted avg. shares (diluted)56.56M56.64M56.67M—56.53M56.51M56.56M—
Balance sheet
Cash & equivalents$726.96M$606.78M$582.65M$566.02M$748.75M$708.86M$697.23M$757.36M
Short-term investments$136.02M$203.67M$201.88M$201.61M———$0
Receivables$151.24M$157.71M$151.55M$158.59M$148.97M$156.95M$147.41M$134.12M
Inventory$182.21M$186.60M$179.26M$170.46M$160.32M$155.86M$153.11M$142.96M
Current assets$1.24B$1.20B$1.16B$1.14B$1.10B$1.06B$1.03B$1.07B
PP&E, net$163.56M$167.51M$173.46M$186.61M$188.93M$193.49M$195.52M$197.74M
Goodwill$1.10B$1.10B$1.11B$1.11B$1.11B$1.11B$1.08B$1.03B
Intangibles$305.29M$357.62M$368.19M$386.15M$395.44M$406.21M$409.23M$397.90M
Total assets$2.93B$2.95B$2.93B$2.95B$2.92B$2.90B$2.85B$2.83B
Current liabilities$125.69M$132.66M$126.21M$135.83M$131.14M$123.01M$152.00M$126.79M
Long-term debt$555.60M$551.05M$546.59M$542.21M$537.93M——$525.57M
Total debt$555.60M$551.05M$546.59M$542.21M$537.93M——$525.57M
Total liabilities$834.67M$838.15M$825.31M$843.57M$840.62M$839.89M$866.66M$856.95M
Shareholders' equity$2.09B$2.11B$2.11B$2.11B$2.08B$2.06B$1.99B$1.97B
Net debt-$171.36M-$55.74M-$36.06M-$23.81M-$210.82M——-$231.79M
Shares outstanding56.69M56.43M56.40M56.33M56.28M56.25M56.18M56.09M
Cash flow statement
Operating cash flow$43.10M$32.77M$28.30M$25.70M$48.10M$28.61M$15.01M$39.18M
Capital expenditure$4.95M$5.33M$4.71M$8.15M$4.70M$7.10M$3.56M$5.54M
Free cash flow$38.15M$27.43M$23.59M$17.55M$43.40M$21.51M$11.44M$33.64M
Investing cash flow$63.99M-$2.09M-$3.99M-$208.74M-$7.78M-$7.84M-$74.11M-$64.76M
Financing cash flow$14.60M-$6.20M-$5.54M$195,000-$239,000-$10.13M-$5.03M$1.45M
Depreciation & amortization$19.12M$19.06M$19.76M$19.95M$20.01M$20.08M$18.70M$18.37M
Stock-based compensation$9.36M$8.01M$8.32M$7.98M$8.97M$8.38M$7.27M$6.36M

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.